Neuraxis (NRXS) EBT Margin (2022 - 2025)

Neuraxis (NRXS) posted EBT Margin of 173.88% for Q4 2025, up 33.75% sequentially from 262.47% in Q3 2025, and up 65.0% YoY from 105.38% in Q4 2024.

Neuraxis (NRXS) EBT Margin (2022 - 2025) Analysis & Trends

Neuraxis has reported EBT Margin for 4 years, with the latest figure at 173.88% in Q4 2025.

Quarterly EBT Margin rose 65.0% year-over-year to 173.88% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 229.82% (up 5637.0% YoY) and the FY2025 annual result came in at 229.49%, up 5857.0% from the prior year.
EBT Margin improved to 173.88% in Q4 2025 per NRXS's latest filing, from 262.47% in the prior quarter.
Over five years, EBT Margin peaked at 103.14% in Q2 2022 and troughed at 654.06% in Q3 2023.
A 4-year average of 258.48% and a median of 234.03% in 2025 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2024: EBT Margin tumbled 44335 bps in 2023, then jumped 39665 bps in 2024.
Over 4 years, EBT Margin stood at 167.63% in 2022, then tumbled by 82 bps to 305.68% in 2023, then soared by 43 bps to 174.53% in 2024, then increased by 0 bps to 173.88% in 2025.
According to Business Quant data, EBT Margin over the past three periods registered 173.88%, 262.47%, and 234.03% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Neuraxis	75.51 Mn	67.18 Mn	-	-

Download Data